HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Kalyn Dabbs

Kalyn Dabbs

Director of Communications

Kalyn Dabbs serves as Genprex’s Director of Communications. Kalyn is responsible for developing and implementing internal and external communication and marketing plans, managing the company’s website and social media strategy, drafting and updating communication materials and providing organizational leadership on communication and marketing initiatives. Kalyn has more than a decade of experience leading external communication programs in both B2B and B2C marketing settings. Prior to joining Genprex, Kalyn has worked for public companies within the health industry, specifically with medical devices and consumer packaged goods, leading global communication and marketing campaigns for commercial FDA-approved products. She has also worked for public relations agencies, serving both public and private clients across a variety of industries while garnering experience in internal and external communications, investor relations, media relations, social media, content development and crisis communications.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex to Participate at BIO Europe Spring 2026 Mar 10
  • Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer Feb 23
  • Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Feb 10
  • Genprex Provides Clinical Update on Diabetes Gene Therapy Program Jan 7
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use